153 related articles for article (PubMed ID: 16731591)
1. The reliability of assessment of oestrogen receptor expression on needle core biopsy specimens of invasive carcinomas of the breast.
Hodi Z; Chakrabarti J; Lee AH; Ronan JE; Elston CW; Cheung KL; Robertson JF; Ellis IO
J Clin Pathol; 2007 Mar; 60(3):299-302. PubMed ID: 16731591
[TBL] [Abstract][Full Text] [Related]
2. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.
Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
Histopathology; 2012 May; 60(6):880-4. PubMed ID: 22320892
[TBL] [Abstract][Full Text] [Related]
3. A comparison of immunohistochemical staining for oestrogen receptor, progesterone receptor and HER-2 in breast core biopsies and subsequent excisions.
Wood B; Junckerstorff R; Sterrett G; Frost F; Harvey J; Robbins P
Pathology; 2007 Aug; 39(4):391-5. PubMed ID: 17676479
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome.
Francis G; Beadle G; Thomas S; Mengersen K; Stein S
Pathology; 2006 Oct; 38(5):391-8. PubMed ID: 17008275
[TBL] [Abstract][Full Text] [Related]
5. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma.
Zidan A; Christie Brown JS; Peston D; Shousha S
J Clin Pathol; 1997 Jan; 50(1):27-9. PubMed ID: 9059351
[TBL] [Abstract][Full Text] [Related]
6. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Helms MW; Packeisen J; August C; Schittek B; Boecker W; Brandt BH; Buerger H
J Pathol; 2005 Jul; 206(3):366-76. PubMed ID: 15892165
[TBL] [Abstract][Full Text] [Related]
7. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
[TBL] [Abstract][Full Text] [Related]
8. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma.
Prasad R; Boland GP; Cramer A; Anderson E; Knox WF; Bundred NJ
Cancer; 2003 Dec; 98(12):2539-46. PubMed ID: 14669271
[TBL] [Abstract][Full Text] [Related]
9. Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
Rakha EA; Pigera M; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
Histopathology; 2016 Jul; 69(1):20-4. PubMed ID: 26542743
[TBL] [Abstract][Full Text] [Related]
10. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.
D'Alfonso T; Liu YF; Monni S; Rosen PP; Shin SJ
Am J Surg Pathol; 2010 Apr; 34(4):575-81. PubMed ID: 20216378
[TBL] [Abstract][Full Text] [Related]
11. Multiplexed tandem polymerase chain reaction identifies strong expression of oestrogen receptor and Her-2 from single, formalin-fixed, paraffin-embedded breast cancer sections.
Thompson EW; Warton K; Blick T; Wafai R; Hill P; Stanley K
Pathology; 2010 Feb; 42(2):165-72. PubMed ID: 20085519
[TBL] [Abstract][Full Text] [Related]
12. Comparison of core oestrogen receptor (ER) assay with excised tumour: intratumoral distribution of ER in breast carcinoma.
Douglas-Jones AG; Collett N; Morgan JM; Jasani B
J Clin Pathol; 2001 Dec; 54(12):951-5. PubMed ID: 11729216
[TBL] [Abstract][Full Text] [Related]
13. Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.
Fernandes RC; Bevilacqua JL; Soares IC; Siqueira SA; Pires L; Hegg R; Carvalho FM
Histopathology; 2009 Sep; 55(3):346-52. PubMed ID: 19723150
[TBL] [Abstract][Full Text] [Related]
14. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
15. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
16. [Determination of estrogen receptors in aspirates from needle biopsies of breast carcinomas. Correlation to a biochemical method].
Sauer T; Naess O; Kåresen R; Jacobsen U; Amlie E; Haug E
Tidsskr Nor Laegeforen; 1994 Apr; 114(9):1053-5. PubMed ID: 8009516
[TBL] [Abstract][Full Text] [Related]
17. [Estrogen receptor studies in breast cancer based on histological material. Correlation with results from needle biopsy aspirates and pS2 protein determination].
Sauer T; Naess O
Tidsskr Nor Laegeforen; 1995 Sep; 115(23):2881-3. PubMed ID: 7570508
[TBL] [Abstract][Full Text] [Related]
18. Semi-quantitative RT-PCR assessment of molecular markers in breast large-core needle biopsies.
Pohlodek K; Galbavý S; Bartosová M; Mucha V; Holomán K; Pastorek J; Pastoreková S
Neoplasma; 2004; 51(6):415-21. PubMed ID: 15640949
[TBL] [Abstract][Full Text] [Related]
19. Do the histologic features and results of breast cancer biomarker studies differ between core biopsy and surgical excision specimens?
Burge CN; Chang HR; Apple SK
Breast; 2006 Apr; 15(2):167-72. PubMed ID: 16095904
[TBL] [Abstract][Full Text] [Related]
20. False-negative assessment of oestrogen receptor on needle core biopsy of invasive carcinoma of the breast.
Lee AH; Hodi Z; Ellis IO
J Clin Pathol; 2008 Feb; 61(2):239-40. PubMed ID: 18223101
[No Abstract] [Full Text] [Related]
[Next] [New Search]
